AkaRx
About:
AkaRx develops therapeutics including the orally-available small molecule for use in the treatment of thrombocytopenia.
Top Investors: Sutter Hill Ventures, InterWest Partners
Description:
AkaRx, Inc., a biopharmaceutical company, develops therapeutic treatments for unmet medical needs. Its product includes AKR-501, an orally-available small molecule for use in the treatment of thrombocytopenia. The company was founded in 2005 and is headquartered in Paramus, New Jersey.
Total Funding Amount:
$21.1M
Headquarters Location:
Paramus, New Jersey, United States
Founded Date:
2005-01-01
Founders:
Number of Employees:
Last Funding Date:
2007-07-13
IPO Status:
Private
Industries:
© 2025 bioDAO.ai